- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06472401
Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students
Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students: Randomized Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Breno S Santana, MsC
- Phone Number: +5561982085031
- Email: bresousas@outlook.com
Study Contact Backup
- Name: Alberto Augusto M Paiva, Nurse
- Phone Number: +5561982085031
- Email: albertopaiva19@hotmail.com
Study Locations
-
-
Federal District
-
Brasilia, Federal District, Brazil, 72220-275
- Care Skills and Simulation Laboratory
-
Contact:
- Marcia Cristina S Magro, PhD
- Phone Number: +5561982690888
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be aged ≥ 18 years old;
- Students enrolled in the last two years of the undergraduate nursing course;
- Students who have self-declared internet access in their homes to complete the course's online modules.
Exclusion Criteria:
- Students who have previous training and/or professional experience in the health area;
- Students who do not complete at least 75% of the workload of the proposed course.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Integrated Learning Support System (ILSS)
For the Experimental Group, in addition to the Standard Learning Model (MPA), an Integrated Learning Support System (ILSS) will be added, consisting of strategies to achieve different learning styles
|
Students will receive simulation preparation with an Integrated Learning Support System consisting of:
|
|
Active Comparator: Standard Learning Model (SLM)
In the Control Group, students will be submitted to the Standard Learning Model (SLM) during the preparation stage for the immersive simulated training, consisting of: use of expository video lessons, participation in doubt forums, reading and critical analysis of scientific articles.
|
Students will receive standard simulation preparation consisting of: - Expository and dialogued theoretical class. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knowledge about Prevention of Contrast-Induced Nephrotoxicity (baseline)
Time Frame: Evaluated one week before participation in the simulation scenario.
|
Assessment of knowledge about prevention of contrast-induced nephrotoxicity using a standardized questionnaire.
Unit of Measure: Percentage of correct responses
|
Evaluated one week before participation in the simulation scenario.
|
|
Knowledge about Prevention of Contrast-Induced Nephrotoxicity (one week before simulation)
Time Frame: Evaluated Immediately after participation in the simulation scenario
|
Assessment of knowledge about prevention of contrast-induced nephrotoxicity using a standardized questionnaire.
Unit of Measure: Percentage of correct responses
|
Evaluated Immediately after participation in the simulation scenario
|
|
Knowledge about Prevention of Contrast-Induced Nephrotoxicity (thirty days after simulation)
Time Frame: Evaluated Thirty days after participation in the simulation scenario
|
Assessment of knowledge about prevention of contrast-induced nephrotoxicity using a standardized questionnaire.
Unit of Measure: Percentage of correct responses
|
Evaluated Thirty days after participation in the simulation scenario
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Practical Performance in Realistic Simulation
Time Frame: During the simulated scenario.
|
This measure evaluates the student's ability to perform specific tasks and procedures accurately and efficiently in a simulated clinical environment.
Assessment of student's practical performance during the realistic simulation scenario using a standardized performance checklist.
Unit of Measure: Percentage of completed tasks according to the performance checklist.
Measurement Tool: Standardized performance checklist
|
During the simulated scenario.
|
|
Clinical Judgment on Prevention of Contrast-Induced Nephrotoxicity (baseline)
Time Frame: Evaluated one week before participation in the simulation scenario
|
Assessment of clinical judgment regarding the prevention of contrast-induced nephrotoxicity using the Lasater Clinical Judgment Rubric - Brazilian Version (LCJR-BV). Unit of Measure: Scores on the LCJR-BV, which range from 11 to 44 points. The scoring system is designed to identify the level of clinical performance presented by an individual and includes four levels for each of the 11 dimensions: One point for each behavior considered "Novice" Two points for behavior considered "Developing" Three points for behavior considered "Proficient" Four points for behavior considered "Exemplary" Scores between 11 and 19 points are considered "Novice"; scores between 20 and 28 points are considered "Developing"; scores between 29 and 37 points are considered "Proficient"; and scores between 38 and 44 points are considered "Exemplary". |
Evaluated one week before participation in the simulation scenario
|
|
Clinical Judgment on Prevention of Contrast-Induced Nephrotoxicity (immediately after simulation)
Time Frame: Evaluated immediately after participation in the simulation scenario
|
Assessment of clinical judgment regarding the prevention of contrast-induced nephrotoxicity using the Lasater Clinical Judgment Rubric - Brazilian Version (LCJR-BV). Unit of Measure: Scores on the LCJR-BV, which range from 11 to 44 points. The scoring system is designed to identify the level of clinical performance presented by an individual and includes four levels for each of the 11 dimensions: One point for each behavior considered "Novice" Two points for behavior considered "Developing" Three points for behavior considered "Proficient" Four points for behavior considered "Exemplary" Scores between 11 and 19 points are considered "Novice"; scores between 20 and 28 points are considered "Developing"; scores between 29 and 37 points are considered "Proficient"; and scores between 38 and 44 points are considered "Exemplary". |
Evaluated immediately after participation in the simulation scenario
|
|
Clinical Judgment on Prevention of Contrast-Induced Nephrotoxicity (thirty days after simulation)
Time Frame: Evaluated thirty days after participation in the simulation scenario
|
Assessment of clinical judgment regarding the prevention of contrast-induced nephrotoxicity using the Lasater Clinical Judgment Rubric - Brazilian Version (LCJR-BV). Unit of Measure: Scores on the LCJR-BV, which range from 11 to 44 points. The scoring system is designed to identify the level of clinical performance presented by an individual and includes four levels for each of the 11 dimensions: One point for each behavior considered "Novice" Two points for behavior considered "Developing" Three points for behavior considered "Proficient" Four points for behavior considered "Exemplary" Scores between 11 and 19 points are considered "Novice"; scores between 20 and 28 points are considered "Developing"; scores between 29 and 37 points are considered "Proficient"; and scores between 38 and 44 points are considered "Exemplary". |
Evaluated thirty days after participation in the simulation scenario
|
|
Depression, Anxiety and Stress (baseline)
Time Frame: Evaluated one week before participation in the simulation scenario
|
Gradation of depression, anxiety, and stress during different stages of the study using the Depression, Anxiety, and Stress Scale - 21 items (DASS-21). Unit of Measure: Scores on the DASS-21, which range from 0 to 63 points, subdivided into three factors: depression, anxiety, and stress. Each factor is assessed using a four-point Likert scale (0 - did not apply at all; 1 - applied to some degree, or for a short time; 2 - applied to a considerable degree, or for a good part of the time; 3 - applied very much, or most of the time). Scoring Interpretation: Depression: Normal (0-9), Mild (10-13), Moderate (14-20), Severe (21-27), Extremely Severe (28+) Anxiety: Normal (0-7), Mild (8-9), Moderate (10-14), Severe (15-19), Extremely Severe (20+) Stress: Normal (0-14), Mild (15-18), Moderate (19-25), Severe (26-33), Extremely Severe (34+) |
Evaluated one week before participation in the simulation scenario
|
|
Depression, Anxiety and Stress (immediately after simulation)
Time Frame: Evaluated immediately after participation in the simulation scenario
|
Gradation of depression, anxiety, and stress during different stages of the study using the Depression, Anxiety, and Stress Scale - 21 items (DASS-21). Unit of Measure: Scores on the DASS-21, which range from 0 to 63 points, subdivided into three factors: depression, anxiety, and stress. Each factor is assessed using a four-point Likert scale (0 - did not apply at all; 1 - applied to some degree, or for a short time; 2 - applied to a considerable degree, or for a good part of the time; 3 - applied very much, or most of the time). Scoring Interpretation: Depression: Normal (0-9), Mild (10-13), Moderate (14-20), Severe (21-27), Extremely Severe (28+) Anxiety: Normal (0-7), Mild (8-9), Moderate (10-14), Severe (15-19), Extremely Severe (20+) Stress: Normal (0-14), Mild (15-18), Moderate (19-25), Severe (26-33), Extremely Severe (34+) |
Evaluated immediately after participation in the simulation scenario
|
|
Depression, Anxiety and Stress (thirty days after simulation)
Time Frame: Evaluated thirty days after participation in the simulation scenario
|
Gradation of depression, anxiety, and stress during different stages of the study using the Depression, Anxiety, and Stress Scale - 21 items (DASS-21). Unit of Measure: Scores on the DASS-21, which range from 0 to 63 points, subdivided into three factors: depression, anxiety, and stress. Each factor is assessed using a four-point Likert scale (0 - did not apply at all; 1 - applied to some degree, or for a short time; 2 - applied to a considerable degree, or for a good part of the time; 3 - applied very much, or most of the time). Scoring Interpretation: Depression: Normal (0-9), Mild (10-13), Moderate (14-20), Severe (21-27), Extremely Severe (28+) Anxiety: Normal (0-7), Mild (8-9), Moderate (10-14), Severe (15-19), Extremely Severe (20+) Stress: Normal (0-14), Mild (15-18), Moderate (19-25), Severe (26-33), Extremely Severe (34+) |
Evaluated thirty days after participation in the simulation scenario
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Marcia CS Magro, PhD, University of Brasilia
- Principal Investigator: Breno S Santana, MsC, University of Brasilia
Publications and helpful links
General Publications
- Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting guidelines for health care simulation research: extensions to the CONSORT and STROBE statements. Adv Simul (Lond). 2016 Jul 25;1:25. doi: 10.1186/s41077-016-0025-y. eCollection 2016.
- Salvarani V, Ardenghi S, Rampoldi G, Bani M, Cannata P, Ausili D, Di Mauro S, Strepparava MG. Predictors of psychological distress amongst nursing students: A multicenter cross-sectional study. Nurse Educ Pract. 2020 Mar;44:102758. doi: 10.1016/j.nepr.2020.102758. Epub 2020 Mar 13.
- Lasater K. Clinical judgment development: using simulation to create an assessment rubric. J Nurs Educ. 2007 Nov;46(11):496-503. doi: 10.3928/01484834-20071101-04.
- Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet. 2002 Jan 19;359(9302):248-52. doi: 10.1016/S0140-6736(02)07451-2.
- Dreifuerst KT. Using debriefing for meaningful learning to foster development of clinical reasoning in simulation. J Nurs Educ. 2012 Jun;51(6):326-33. doi: 10.3928/01484834-20120409-02. Epub 2012 Apr 9.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 55509622.9.3001.5650
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrotoxicity
-
Minia UniversityMinia University HospitalRecruitingNephrotoxicity | Cisplatin NephrotoxicityEgypt
-
Tanta UniversityRecruiting
-
Regional Hospital HolstebroUnknown
-
Ain Shams UniversityNot yet recruitingNephrotoxicityEgypt
-
University of Colorado, DenverMemorial Sloan Kettering Cancer Center; National Institute of General Medical... and other collaboratorsActive, not recruiting
-
University at BuffaloCubist Pharmaceuticals LLCCompleted
-
Ain Shams UniversityCompleted
-
Soroka University Medical CenterCompletedDrug Induced NephrotoxicityIsrael
-
Instituto Nacional de Ciencias Medicas y Nutricion...RecruitingSolid Tumors | Cisplatin NephrotoxicityMexico
-
Ain Shams UniversityCompleted
Clinical Trials on Integrated Learning Support System
-
University of UtahHitachi, Ltd.CompletedDiabetes Mellitus, Type 2 | Diabetes MellitusUnited States
-
Karen KlassenNational Health and Medical Research Council, Australia; Monash University; The... and other collaboratorsCompletedCardiovascular Disease | HIVAustralia
-
University of PisaNot yet recruiting
-
Universiti Putra MalaysiaTakeda Malaysia Sdn. Bhd.Not yet recruitingKnowledge, Attitudes, PracticeMalaysia
-
Shanghai 6th People's HospitalUniversity of North Carolina, Chapel Hill; Merck FoundationCompletedPreDiabetes | Type2 DiabetesChina
-
Prince of Songkla UniversityCompletedPregnant AdolescentsPalestinian Territory, occupied
-
Arizona State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationImplementation Science | Diet, Food, and Nutrition | Child Care | Motor BehaviorUnited States
-
Ankara Yildirim Beyazıt UniversityRecruiting
-
Qun ZhaoNot yet recruiting
-
Rhode Island HospitalActive, not recruitingMyocardial Infarction | Pneumonia | Hospital Readmission | COPD